[177Lu-DOTA0,Tyr3]-octreotate in the treatment of midgut neuroendocrine tumors.

Related Articles

[177Lu-DOTA0,Tyr3]-octreotate in the treatment of midgut neuroendocrine tumors.

Future Oncol. 2016 Feb;12(3):313-21

Authors: Halperin DM, Dasari A, Yao JC

Abstract
Midgut neuroendocrine tumors (NETs) are relatively rare and remarkably heterogeneous. Although recent developments for pancreatic NETs have brought multiple new therapies to patients who need them, there has been little observed efficacy against midgut NETs. Peptide receptor radionuclide therapy utilizes somatostatin analogs conjugated to radioactive isotopes in order to deliver high doses of radiation directly to tumor cells, which express somatostatin receptors. Peptide receptor radionuclide therapy with [(177)Lu-DOTA(0),Tyr(3)]-octreotate (DOTATATE) has been reported and investigated for more than a decade, and the randomized controlled NETTER-1 study of this agent has recently been reported to show promising results. In this article, we will summarize and evaluate the rationale and existing clinical data for the activity of DOTATATE in midgut NETs, to give context for the interpretation of NETTER-1 results when they are fully available.

PMID: 26759064 [PubMed - indexed for MEDLINE]

http://ift.tt/2iwSTxu